Home / Business and Economy / Oregon Lands $750M Roche/Genentech Pharma Plant
Oregon Lands $750M Roche/Genentech Pharma Plant
21 Aug
Summary
- Roche invests $750 million in a new injectable manufacturing site in Oregon.
- The facility in Hillsboro will create approximately 200 construction jobs.
- It will employ 250 skilled specialists once operational by 2031.
Roche's subsidiary, Genentech, is establishing a new $750 million injectable manufacturing facility in Hillsboro, Oregon. This expansion will increase the company's presence within the United States.
The proposed end-to-end fill-finish production site will be situated on the same campus as Genentech's existing Hillsboro facility. It is designed for flexibility, capable of handling both low and high-volume autoinjectors and pre-filled syringes, catering to the industry's shift towards at-home use formats.
Construction is slated to begin soon, employing approximately 200 workers until the facility's projected completion in 2031. Upon becoming operational, the site will house around 250 skilled manufacturing specialists.
This investment aligns with a broader trend of major pharmaceutical companies increasing their US manufacturing footprint. Roche is also developing a $2 billion biomanufacturing site in Holly Springs, North Carolina, which will focus on therapies for metabolic conditions.
